Alterations of pituitary adenylate cyclase-activatinq polypeptide-like immunoreactivity in the human plasma during pregnancy and after birth

Journal of Endocrinological Investigation

Volumn 33, Issue 7, 2010, Pages 443-445

  Reglodi, D ^a   Gyarmati, J ^b   Ertl, T ^b   Borzsei, R ^b   Bodis, J ^b   Tamas, A ^a   Kiss, P ^a   Csanaky, K ^a   Banki, E ^a   Bay, C ^b   Nemeth, J ^c   Helyes, Z ^b  

^a UNIVERSITY OF PÉCS   (Hungary)

^b UNIVERSITY OF PÉCS   (Hungary)

^c UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Delivery; Newborn; PACAP; RIA; Umbilical vessels

Indexed keywords

HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; FEMALE; FETUS; GESTATION PERIOD; HORMONAL REGULATION; HUMAN; IMMUNOREACTIVITY; NEWBORN; NORMAL HUMAN; PREGNANCY; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS; PUERPERIUM; RADIOIMMUNOASSAY; SECOND TRIMESTER PREGNANCY; THIRD TRIMESTER PREGNANCY; UMBILICAL ARTERY; UMBILICAL CORD BLOOD; UMBILICAL VEIN;

EID: 77957259260     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.1007/BF03346621     Document Type: Article

References (22)

1. Vaudry D, Falluel-Morel A, Bourgault S, et al. Pituitary adenylate cyclase activating polypeptide and its receptors: 20 years after the discovery. Pharmacol Rev 2009, 61: 283-357.
2. Moore JP Jr, Burger LL, Dalkin AC, Winters SJ. Pituitary adenylate cyclase activating polypeptide messenger RNA in the paraventricular nucleus and anterior pituitary during the rat estrous cycle. Biol Reprod 2005, 73: 491-9.
3. Levy G, Jackson K, Degani G. Association between pituitary adenylate cyclase activating polypeptide and reproduction in the blue gourami. Gen Comp Endocrinol 2010, 166: 83-93.
4. Tohei A, Ikeda M, Hokao R, Shinoda M. The different effects of i.c.v. injection of pituitary adenylate cyclase activating polypeptide (PACAP) on prolactin secretion in adult male and lactating rats. Exp Anim 2009, 58: 489-95.
5. Murck H, Steiger A, Frieboes RM, Antonijevic IA. Pituitary adenylate cyclase-activating peptide affects homeostatic sleep regulation in healthy young men. Am J Physiol Encorinol Metab 2007, 292: E853-7. (Pubitemid 46411064)
6. Huang SK, Pan JT. Stimulatory effects of vasoactive intestinal peptide and pituitary adenylate cyclase activating peptide on tuberoin-fundibular dopaminergic neuron activity in estrogen treated ovariectomized rats and their correlation with prolactin secretion. Neuroendocrinology 1996, 64: 208-14.
7. Lee J, Park HJ, Choi HS, et al. Gonadotropin stimulation of pituitary adenylate cyclase activating polypeptide (PACAP) messenger ribonucleic acid in the rat ovary and the role of PACAP as a follicle survival factor. Endocrinology 1999, 140: 818-26.
8. Isaac ER, Sherwood NM. Pituitary adenylate cyclase activating polypeptide (PACAP) is important for embryo implantation in mice. Mol Cell Endocrinol 2008, 280: 13-9.
9. Steenstrup BR, Jorgensen JC, Alm P, et al. Pituitary adenylate cyclase activating polypeptide (PACAP): occurrence and vasodilatory effect in the human uteroplacental unit. Regul Pept 1996, 61: 197-204.
10. Reglodi D, Borzsei R, Bagoly T, et al. Agonistic behavior of PACAP6-38 on sensory nerve terminals and cytotrophoblast cells. J Mol Neurosci 2008, 36: 270-8.
11. Somogyvári-Vigh A, Reglodi D. Pituitary adenylate cyclase activating polypeptide: a potential neuroprotective peptide. Curr Pharm Des 2004, 10: 2861-89. (Pubitemid 39172068)
12. Dow RC, Bennie J, Fink G. Pituitary adenylate cyclase-activating peptide-38 (PACAP)-38 is released into hypophysial portal blood in the normal male and female rat. J Endocrinol 1994,142: R1-4.
13. Palkovits M, Somogyvári-Vigh A, Arimura A. Concentrations of pituitary adenylate cyclase activating polypeptide (PACAP) in human brain nuclei. Brain Res 1995, 699: 116-20.
14. Bourgault S, Vaudry D, Botia B, et al. Novel stable PACAP analogs with potent activity towards the PAC1 receptor. Peptides 2008, 29: 919-32.
15. Borzsei R, Mark L, Tamas A, et al. Presence of pituitary adenylate cyclase activating polypeptide-38 in human plasma and milk. Eur J Endocrinol 2009, 160: 561-5.
16. Chiodera P, Volpi R, Capretti L, Coiro V. Effects of intravenously infused pituitary adenylate cyclase activating polypeptide on arginin vasopressin and oxytocin secretion in man. Neuroreport 1995, 6: 1490-2.
17. García-Fernández MO, Collado B, Bodega G, et al. Pituitary adenylate cyclase activating peptide/vasoactive intestinal peptide receptors in human normal mammary gland and breast cancer tissue. Gynecol Endocrinol 2005, 20: 327-33.
18. Hong X, Huang L, Song Y. Role of vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide in the vaginal wall of women with stress urinary incontinence and pelvic organ prolapse. Int Urogynecol J Pelvic Floor Dysfunct 2008, 19: 1151-7.
19. Brubel R, Boronkai A, Reglodi D, et al. Changes in the expression of pituitary adenylate cyclase activating polypeptide in the human placenta during pregnancy and its effects on survival of JAR choriocarcinoma cells. J Mol Neurosci 2010, May 7 [Epub ahead of print]; doi: 10.1007/s12031-010-9374-5.
20. Ottesen B, Ulrichsen H, Fahrenkrug J, et al. Vasoactive intestinal polypeptide and the female genital tract: relationship to reproductive phase and delivery. Am J Obstet Gynecol 1982, 143: 414-20. (Pubitemid 12123753)
21. Spencer F, Chi L, Zhu M. Temporal relationships among uterine pituitary adenylate cyclase activating polypeptide, decidual prolactin-related protein and progesterone receptor mRNAs expressions during decidualization and gestation in rats. Comp Biochem Physiol C Toxicol Pharmacol 2001, 129: 25-34.
22. Ganea D, Rodriguez R, Delgado M. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide: players in innate and adaptive immunity. Cell Mol Biol (Noisy-le-grand) 2003, 49: 127-42.